Yearly viral cases and generation time estimations

Numbers in bold indicate estimated viral census size N (cases/year) taken for calculation of N/Ne ratio. Generation time *t* are estimates based on incubation period, onset of viremia and time within vector.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Virus** | **Cases/year**  **[mio]** | **Incubation period [d]** | **Contagious (from)** | **Time within vector [d]** | **Generation time *t* [d]** |
| BCoV1 | **1600 1** | 2-5 2 | With onset of symptoms 2 | *N/A* | 6 |
| CHIKV | **0.5** (0.1-1.5) 3 | 4-8 4 | First week of illness 4 | 2-3 3 | 12 |
| DENV | **200** (100-400) 5 | 7 (4-10) 5 | 2 days before fever 5 | 10 (8-12) 5 | 17 |
| Ebola | **0.0008** 6 | 9 (2-20)6 | With onset of symptoms 6 | *N/A* | 15 |
| EVA | **38** 7,8 | 4 (3-6) 2 | Within first week of symptoms 9 | *N/A* | 7 |
| EVB | **168** (-500) 8,10 | 4 (3-6) 2 | Within first week of symptoms 9 | *N/A* | 7 |
| EVC | **26** (-100) 8,10 | 4 (3-6) 2 | Within first week of symptoms 9 | *N/A* | 7 |
| EVD | **7** (-70) 8,10 | 4 (3-6) 2 | Within first week of symptoms 9 | *N/A* | 7 |
| Flu H3N2 | **780** 11 | 212 | 3-412 | *N/A* | 5 |
| HCV | **1.75** 13 | 60 (14-180)13 | After incubation period | *N/A* | 180 |
| HDV | **1** (estim. Based on preval.14) | 14-60 15 | After incubation period | *N/A* | 150 |
| HMPV | **75 16** | 3-52 | Few days after incubation period17 | *N/A* | 7 |
| HRSV | **64** 18 | 5 (2-8) 18 | 7 days post symptoms 19 | *N/A* | 12 |
| HRV3 | **84** 2 | 2-6 2 | Day 2 post infection 2 | *N/A* | 5 |
| MERS | **0.00031** 20 | 5 (2-14) 21 | After incubation period | *N/A* | 10 |
| MMV | **10** 22 | 10-12 23 | 10 d post infection 24 | *N/A* | 14 |
| MRV | **0.07** (-0.7) 25 | 16-18 26 | Few days before symptoms 26 | *N/A* | 14 |
| Norwalk | **685** 27 | 1-2 27 | 1d post infection | *N/A* | 3 |
| OHVA | **20** 28 | 25-30 28 | Few days before symptoms | *N/A* | 42 |
| PeVA | **70** 29 | 4 (based on other picornas) | Shortly after onset of symptoms 2 | *N/A* | 7 |
| RVA | **2600** 2 | 22 | During first days of symptoms2 | *N/A* | 5 |
| SARS-CoV-2 | **106** 30 | 6-14 31 | 8d post symptoms 31 | *N/A* | 14 |
| SV | **116 32** | 1-4 33 | With start of symptoms 33 | *N/A* | 5 |
| YFV | **0.2** 34 | 3-6 35 | 5 34 | 9-12 36 | 15 |
| ZIKV | **0.5** 37 | 3-14 38 | 3-5d post symptoms 37 | 9-12 36 | 20 |

1 Liu, D. X., Liang, J. Q. & Fung, T. S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). *Encyclopedia of Virology*, 428-440, doi:10.1016/B978-0-12-809633-8.21501-X (2021).

2 Kimberlin, D. W. *Red Book: 2018-2021 report of the committee on infectious diseases*. (American academy of pediatrics, 2018).

3 organisation, W. h. *Chikungunya fact sheets*, <<https://www.who.int/news-room/fact-sheets/detail/chikungunya>> (2020).

4 CDC, C. f. D. C. a. P. *CHIKV For Health Care Providers*, <<https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html>> (2021).

5 Organisation, W. H. *Dengue and severe dengue fact sheets*, <<https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>> (2020).

6 CDC, C. f. D. C. a. P. *Ebola (Ebola Virus Disease)*, <<https://www.cdc.gov/vhf/ebola/index.html>> (2021).

7 Shi, L., Zhao, H. & Wu, D. Modelling and analysis of HFMD with the effects of vaccination, contaminated environments and quarantine in mainland China. *Math Biosci Eng* **16**, 474-500, doi:10.3934/mbe.2019022 (2018).

8 CDC, C. f. D. C. a. P. *Non-polio Enteroviruses*, <<https://www.cdc.gov/non-polio-enterovirus/index.html>> (2021).

9 CDC, C. f. D. C. a. P. *HFMD*, <<https://www.cdc.gov/hand-foot-mouth/about/transmission.html>> (2021).

10 Brouwer, L., Moreni, G., Wolthers, K. C. & Pajkrt, D. World-Wide Prevalence and Genotype Distribution of Enteroviruses. *Viruses* **13**, doi:10.3390/v13030434 (2021).

11 Peteranderl, C., Herold, S. & Schmoldt, C. Human Influenza Virus Infections. *Semin Respir Crit Care Med* **37**, 487-500, doi:10.1055/s-0036-1584801 (2016).

12 CDC, C. f. D. C. a. P. *Influenza*, <<https://www.cdc.gov/flu/index.htm>> (2021).

13 Organisation, W. H. *Hepatitis C fact sheets*, <<https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>> (2020).

14 Lempp, F. A., Ni, Y. & Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. *Nat Rev Gastroenterol Hepatol* **13**, 580-589, doi:10.1038/nrgastro.2016.126 (2016).

15 Negro, F. Hepatitis D virus coinfection and superinfection. *Cold Spring Harb Perspect Med* **4**, a021550, doi:10.1101/cshperspect.a021550 (2014).

16 Shafagati, N. & Williams, J. Human metapneumovirus - what we know now. *F1000Res* **7**, 135, doi:10.12688/f1000research.12625.1 (2018).

17 Schuster, J. E. & Williams, J. V. Human metapneumovirus. *Pediatr Rev* **34**, 558-565, doi:10.1542/pir.34-12-558 (2013).

18 Krause, C. I. The ABCs of RSV. *Nurse Pract* **43**, 20-26, doi:10.1097/01.Npr.0000544277.74514.55 (2018).

19 Takeyama, A. *et al.* Respiratory syncytial virus shedding by children hospitalized with lower respiratory tract infection. *J Med Virol* **88**, 938-946, doi:10.1002/jmv.24434 (2016).

20 WHO, W. H. O. e. *MERS emro*, <<http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html>> (2021).

21 CDC, C. f. D. C. a. P. *MERS*, <<https://www.cdc.gov/coronavirus/mers/clinical-features.html>> (2021).

22 Organisation, W. H. *Measles fact-sheets*, <<https://www.who.int/news-room/fact-sheets/detail/measles>> (2019).

23 Organisation, W. H. *Measles news*, <<https://www.who.int/news/item/05-12-2019-more-than-140-000-die-from-measles-as-cases-surge-worldwide>> (2019).

24 CDC, C. f. D. a. P. *Measles transmission*, <<https://www.cdc.gov/measles/transmission.html>> (2021).

25 Su, S. B., Chang, H. L. & Chen, A. K. Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine. *Int J Environ Res Public Health* **17**, doi:10.3390/ijerph17051686 (2020).

26 CDC, C. f. D. C. a. P. *Mumps*, <<https://www.cdc.gov/mumps/index.html>> (2021).

27 CDC, C. f. D. C. a. P. *Noro*, <<https://www.cdc.gov/norovirus/trends-outbreaks/worldwide.html>> (2021).

28 Organisation, W. H. *Hepatitis E Virus fact-sheets*, <<https://www.who.int/news-room/fact-sheets/detail/hepatitis-e>> (2020).

29 Shah, G. & Robinson, J. L. The particulars on parechovirus. *Can J Infect Dis Med Microbiol* **25**, 186-188, doi:10.1155/2014/602501 (2014).

30 Organisation, W. H. *SARS-CoV-2 newsroom*, <<https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>> (2020).

31 Organisation, W. H. *WHO Coronavirus (COVID-19) Dashboard*, <<https://covid19.who.int/>> (2021).

32 Diez Valcarce, M. *et al.* Global distribution of sporadic sapovirus infections: A systematic review and meta-analysis. *PLoS One* **16**, e0255436, doi:10.1371/journal.pone.0255436 (2021).

33 Oka, T., Wang, Q., Katayama, K. & Saif, L. J. Comprehensive review of human sapoviruses. *Clin Microbiol Rev* **28**, 32-53, doi:10.1128/cmr.00011-14 (2015).

34 CDC, C. f. D. C. a. P. *Yellow fever virus newsroom*, <<https://www.cdc.gov/globalhealth/newsroom/topics/yellowfever/index.html>> (2021).

35 Organisation, W. H. *Yellow Fever Virus fact-sheets*, <<https://www.who.int/news-room/fact-sheets/detail/yellow-fever>> (2019).

36 Huang, Y. J., Higgs, S., Horne, K. M. & Vanlandingham, D. L. Flavivirus-mosquito interactions. *Viruses* **6**, 4703-4730, doi:10.3390/v6114703 (2014).

37 Nugent, E. K., Nugent, A. K., Nugent, R. & Nugent, K. Zika Virus: Epidemiology, Pathogenesis and Human Disease. *Am J Med Sci* **353**, 466-473, doi:10.1016/j.amjms.2016.12.018 (2017).

38 Organisation, W. H. *Zika virus fact sheets*, <<https://www.who.int/news-room/fact-sheets/detail/zika-virus>> (2018).